1.A core epitope targeting antibody of SARS-CoV-2.
Simeng ZHAO ; Fengjiang LIU ; Shizhen QIU ; Qiaoshuai LAN ; Yiran WU ; Wei XU ; Junzi KE ; Jie YANG ; Xiaoyan LIU ; Kun WANG ; Hangtian GUO ; Shuai XIA ; Fangfang ZHANG ; Jiabei WANG ; Xiaowen HU ; Lu LU ; Shibo JIANG ; Suwen ZHAO ; Lianxin LIU ; Youhua XIE ; Xiuna YANG ; Haopeng WANG ; Guisheng ZHONG
Protein & Cell 2023;14(1):74-78
2.Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections.
Rongtao LAI ; Tianhui ZHOU ; Xiaogang XIANG ; Jie LU ; Haiguang XIN ; Qing XIE
Frontiers of Medicine 2021;15(4):644-648
The coronavirus disease 2019 (COVID-19) has caused global public health and economic crises. Thus, new therapeutic strategies and effective vaccines are urgently needed to cope with this severe pandemic. The development of a broadly neutralizing antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the attractive treatment strategies for COVID-19. Currently, the receptor-binding domain (RBD) of the spike (S) protein is the main target of neutralizing antibodies when SARS-CoV-2 enters human cells through an interaction between the S protein and the angiotensin-converting enzyme 2 expressed on various human cells. A single monoclonal antibody (mAb) treatment is prone to selective pressure due to increased possibility of targeted epitope mutation, leading to viral escape. In addition, the antibody-dependent enhancement effect is a potential risk of enhancing the viral infection. These risks can be reduced using multiple mAbs that target nonoverlapping epitopes. Thus, a cocktail therapy combining two or more antibodies that recognize different regions of the viral surface may be the most effective therapeutic strategy.
Antibodies, Monoclonal/therapeutic use*
;
Antibodies, Neutralizing
;
Antibodies, Viral
;
COVID-19
;
Humans
;
SARS-CoV-2
;
Spike Glycoprotein, Coronavirus
3.Mechanism of intravenous immunoglobulin therapy for severe hand-foot-mouth disease: a review.
Ruiyuan CAO ; Jianfeng HAN ; Ede QIN ; Chengfeng QIN
Chinese Journal of Biotechnology 2011;27(5):712-716
Hand-foot-mouth disease (HFMD) is an acute infectious disease caused by various enteroviruses. Recently, large HFMD outbreaks caused by enterovirus type 71 (EV71) have been frequently reported in China, posing great threats on children's health. There is no specific antiviral therapy for severe HFMD, and patient management mainly depends on supportive and symptomatic treatment. Intravenous immunoglobulin (IVIG) is a pharmaceutical preparation of human IgG that is pooled from thousands of healthy blood donors, and contained neutralization antibodies against various enteroviruses, including EV71. IVIG therapy should be carefully administrated for severe HFMD considering its role on passive immunization against EV71 and immune regulation.
Antibodies, Neutralizing
;
immunology
;
therapeutic use
;
Antibodies, Viral
;
immunology
;
therapeutic use
;
Enterovirus A, Human
;
immunology
;
Hand, Foot and Mouth Disease
;
therapy
;
virology
;
Humans
;
Immunization, Passive
;
Immunoglobulins, Intravenous
;
immunology
;
therapeutic use
4.Does the homologous booster with the inactivated coronavirus disease 2019 vaccine work for the omicron variant? Real-world evidence from Jilin, China.
Jun GUO ; Lei ZHA ; Kai ZENG ; Mingyu SHAO ; Dan CHEN ; Bing WANG ; Yun ZHOU ; Gang YANG ; Xue ZHANG ; Xia ZOU ; Yan ZHANG ; Yan KANG
Chinese Medical Journal 2023;136(23):2892-2894
6.Progress on the development of the SARS-CoV-2 vaccine and antibody drugs.
Journal of Biomedical Engineering 2022;39(5):1059-1064
The raging global epidemic of coronavirus disease 2019 (COVID-19) not only poses a major threat to public health, but also has a huge impact on the global health care system and social and economic development. Therefore, accelerating the development of vaccines and antibody drugs to provide people with effective protection and treatment measures has become the top priority of researchers and medical institutions in the field. At present, several vaccines and antibody drugs targeting SARS-Cov-2 have been in the stage of clinical research or approved for marketing around the world. In this manuscript, we summarized the vaccines and antibody drugs which apply genetic engineering technologies to target spike protein, including subunit vaccines, viral vector vaccines, DNA vaccines, mRNA vaccines, and several neutralizing antibody drugs, and discussed the trends of vaccines and antibody drugs in the future.
Humans
;
COVID-19 Vaccines
;
SARS-CoV-2
;
Spike Glycoprotein, Coronavirus
;
COVID-19/prevention & control*
;
Antibodies, Viral
;
Viral Vaccines/therapeutic use*
;
Antibodies, Neutralizing
7.Consistency analysis and clinical guiding significance of cytomegalovirus nucleic acid and antibody detections in patients with different clinical characteristics.
Ju Hua DAI ; Xin Ping SUN ; Jie ZHANG ; Lian Jie SHI
Journal of Peking University(Health Sciences) 2022;54(2):267-271
OBJECTIVE:
To investigate the consistency of cytomegalovirus deoxyribo nucleic acid (CMV-DNA) and immunoglobulin M (IgM) antibody detections in patients with different clinical characteristics and their guiding value for clinical practice.
METHODS:
From December 2014 to November 2019, a total of 507 patients who were detected with both CMV-IgM and CMV-DNA were collected in Peking University International Hospital. Their general information, such as gender, age and clinical data, including the patient's diagnosis, medication, and outcome were also collected. The groups were stratified according to whether CMV-DNA was negative or positive, CMV-IgM was negative or positive, age, gender, and whether they received immunosuppressive therapy or not. The Pearson Chi-square test or Fisher's exact test was used for comparison of the rates between the groups. P < 0.05 means the difference is statisti-cally significant.
RESULTS:
Of the 507 patients submitted for examination, 55 (10.85%) were positive for CMV-DNA, 74 (14.60%) were positive for CMV-IgM, and 20 (3.94%) were positive for both CMV-DNA and CMV-IgM. Of the 55 patients with CMV-DNA positive, 37 were male, accounting for 67.27%. In addition, 25 patients were older than 60 years, accounting for 45.45% and 33 patients received immunosuppressive therapy, accounting for 60%. The rates were higher than that of CMV-DNA negative group, 47.35% (P=0.005), 68.14% (P=0.043), 46.02% (P=0.050), respectively. Of the patients with both CMV-DNA and IgM positive, 45% received immunosuppressive threapy, which was lower than that of CMV-DNA positive but IgM negative patients (68.57%, P=0.086), and also lower than CMV-DNA negative but IgM positive patients (68.52%, P=0.064). In the patients with both CMV-DNA and IgM positive, 91.67% showed remission after receiving ganciclovir, whereas in the patients with CMV-DNA positive but IgM negative, the rate was only 60% (P=0.067).
CONCLUSION
CMV-IgM antibody detection is affected by age, gender, and immune status. It is not recommended to use CMV-IgM alone to determine CMV infection in patients with immunosuppressive status and those older than 60 years. CMV-DNA and CMV-IgM combined detection may help to predict patients' immune status and outcomes of antiviral therapy.
Antibodies, Viral
;
Cytomegalovirus/genetics*
;
Cytomegalovirus Infections/drug therapy*
;
DNA
;
Female
;
Humans
;
Immunoglobulin M
;
Immunosuppressive Agents/therapeutic use*
;
Male
;
Nucleic Acids
8.Durable natural killer cell response after three doses of SARS-CoV-2 inactivated vaccine in HIV-infected individuals.
Xiaodong YANG ; Xiuwen WANG ; Xin ZHANG ; Haifeng DING ; Hu WANG ; Tao HUANG ; Guanghui ZHANG ; Junyi DUAN ; Wei XIA ; Bin SU ; Cong JIN ; Hao WU ; Tong ZHANG
Chinese Medical Journal 2023;136(24):2948-2959
BACKGROUND:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine can induce a potent cellular and humoral immune response to protect against SARS-CoV-2 infection. However, it was unknown whether SARS-CoV-2 vaccination can induce effective natural killer (NK) cell response in people living with human immunodeficiency virus (PLWH) and healthy individuals.
METHODS:
Forty-seven PLWH and thirty healthy controls (HCs) inoculated with SARS-CoV-2 inactivated vaccine were enrolled from Beijing Youan Hospital in this study. The effect of SARS-CoV-2 vaccine on NK cell frequency, phenotype, and function in PLWH and HCs was evaluated by flow cytometry, and the response of NK cells to SARS-CoV-2 Omicron Spike (SARS-2-OS) protein stimulation was also evaluated.
RESULTS:
SARS-CoV-2 vaccine inoculation elicited activation and degranulation of NK cells in PLWH, which peaked at 2 weeks and then decreased to a minimum at 12 weeks after the third dose of vaccine. However, in vitro stimulation of the corresponding peripheral blood monocular cells from PLWH with SARS-2-OS protein did not upregulate the expression of the aforementioned markers. Additionally, the frequencies of NK cells expressing the activation markers CD25 and CD69 in PLWH were significantly lower than those in HCs at 0, 4 and 12 weeks, but the percentage of CD16 + NK cells in PLWH was significantly higher than that in HCs at 2, 4 and 12 weeks after the third dose of vaccine. Interestingly, the frequency of CD16 + NK cells was significantly negatively correlated with the proportion of CD107a + NK cells in PLWH at each time point after the third dose. Similarly, this phenomenon was also observed in HCs at 0, 2, and 4 weeks after the third dose. Finally, regardless of whether NK cells were stimulated with SARS-2-OS or not, we did not observe any differences in the expression of NK cell degranulation markers between PLWH and HCs.
CONCLUSION
s:SARS-CoV-2 vaccine elicited activation and degranulation of NK cells, indicating that the inoculation of SARS-CoV-2 vaccine enhances NK cell immune response.
Humans
;
COVID-19 Vaccines/therapeutic use*
;
COVID-19
;
SARS-CoV-2
;
Killer Cells, Natural
;
HIV Infections
;
Antibodies, Viral
9.Clinical significance of neutralizing anti-interferon antibodies in chronic hepatitis B patients treated with recombinant interferon-alpha.
Qian-guo MAO ; Kang-xian LUO ; Ding-li LIU ; Ming-xia ZHANG ; Jin-lin HOU
Chinese Journal of Hepatology 2004;12(4):205-207
OBJECTIVETo investigate the clinical significance of neutralizing anti-interferon-alpha antibodies (NA) in chronic hepatitis B patients treated with recombinant interferon-alpha(rIFN-alpha).
METHODSOne hundred and eighty-one patients (128 male and 53 female) with histological proven chronic hepatitis B were treated with 5 MU recombinant interferon-alpha 1b (rIFN-alpha 1b) subcutaneously thrice weekly for 6 to 37 (median 10) months. For each patient, Specific detection of serum HBV DNA level with fluorescent-quantitative PCR, HBeAg with enzymoimmunoassay and NA with an antiviral neutralizing biological assay were performed during therapy.
RESULTSNA was found in 61 (33.7%) of 181 patients. At the end of treatment, complete-response was achieved in 17 (27.9%) of 61 patients with NA and in 54 (45.0%) of 120 patients without NA, respectively (chi2=4.979). For NA positive patients, the complete-response rate was significantly lower in those who had not achieved partial-response prior to or at the same time as NA occurred than in those who did (3.8%, 1/26, vs. 45.7%, 16/35, chi2 = 7.457). Moreover, it was lower in patients who either had 20pg/ml of serum HBV DNA or above or HBV DNA had being reduced by less than 60% recent 3 months, but higher in those who had less than 20pg/ml of HBV DNA and HBV DNA had being reduced by 60% or above (20.0%, 9/45, vs. 56.3%, 9/16, chi2 = 11.009).
CONCLUSIONNA may negate the antiviral effects of rIFN-alpha in chronic hepatitis B patients treated with rIFN-alpha, especially if they appear before partial-response or at the occasion at which serum HBV DNA level was not below 20pg/ml or HBV DNA had being reduced by less than 60% recent 3 months.
Antibodies ; blood ; DNA, Viral ; blood ; Female ; Hepatitis B, Chronic ; drug therapy ; virology ; Humans ; Interferon-alpha ; immunology ; therapeutic use ; Male ; Recombinant Proteins ; therapeutic use
10.A broadly neutralizing human monoclonal antibody against the hemagglutinin of avian influenza virus H7N9.
Jingxin LI ; Li ZHANG ; Linlin BAO ; Yuxiao WANG ; Lin QIU ; Jialei HU ; Rong TANG ; Huiyan YU ; Jun SHAN ; Yan LI ; Chuan QIN ; Fengcai ZHU
Chinese Medical Journal 2022;135(7):799-805
BACKGROUND:
The new emerging avian influenza A H7N9 virus, causing severe human infection with a mortality rate of around 41%. This study aims to provide a novel treatment option for the prevention and control of H7N9.
METHODS:
H7 hemagglutinin (HA)-specific B cells were isolated from peripheral blood plasma cells of the patients previously infected by H7N9 in Jiangsu Province, China. The human monoclonal antibodies (mAbs) were generated by amplification and cloning of these HA-specific B cells. First, all human mAbs were screened for binding activity by enzyme-linked immunosorbent assay. Then, those mAbs, exhibiting potent affinity to recognize H7 HAs were further evaluated by hemagglutination-inhibiting (HAI) and microneutralization in vitro assays. Finally, the lead mAb candidate was selected and tested against the lethal challenge of the H7N9 virus using murine models.
RESULTS:
The mAb 6-137 was able to recognize a panel of H7 HAs with high affinity but not HA of other subtypes, including H1N1 and H3N2. The mAb 6-137 can efficiently inhibit the HA activity in the inactivated H7N9 virus and neutralize 100 tissue culture infectious dose 50 (TCID50) of H7N9 virus (influenza A/Nanjing/1/2013) in vitro, with neutralizing activity as low as 78 ng/mL. In addition, the mAb 6-137 protected the mice against the lethal challenge of H7N9 prophylactically and therapeutically.
CONCLUSION
The mAb 6-137 could be an effective antibody as a prophylactic or therapeutic biological treatment for the H7N9 exposure or infection.
Animals
;
Antibodies, Monoclonal/therapeutic use*
;
Antibodies, Neutralizing/therapeutic use*
;
Antibodies, Viral
;
Hemagglutinins
;
Humans
;
Influenza A Virus, H1N1 Subtype
;
Influenza A Virus, H3N2 Subtype
;
Influenza A Virus, H7N9 Subtype
;
Influenza Vaccines
;
Influenza in Birds
;
Influenza, Human/prevention & control*
;
Mice